Indalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965 – Oral integrin antagonist inhibits multiple processes of pathologic fibrosis – Indalo to present at […]
Read MoreBRISBANE, Calif. and ST. LOUIS–(BUSINESS WIRE)–Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced a successful $50 million Series […]
Read MoreST. LOUIS, MO—March 19, 2019—Benson Hill Biosystems, a crop improvement company unlocking the natural diversity of plants, announced today at the World Agri-Tech Innovation Summit that it has acquired the […]
Read MoreBioGenerator-supported startup noted for its ‘promising process’ to more quickly and affordably bring vaccines to market St. Louis bioscience startup VaxNewMo is developing broader and more affordable vaccines faster with […]
Read MoreArch Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of AO-176, an Anti-CD47 Antibody with a Best-in-class Profile — Phase 1 Clinical Trial to Evaluate AO-176 for the […]
Read MoreArvegenix Changes Name to CoverCress Inc.; Secures $2 Million in New Financing for Novel Crop Development ST. LOUIS (Nov. 14, 2018) – CoverCress Inc. (formerly Arvegenix Inc.), recently closed a $2 […]
Read MoreMediBeacon’s Breakthrough Device is Intended to Measure GFR in Patients with Impaired or Normal Kidney Function ST. LOUIS, Oct. 22, 2018 /PRNewswire/ — MediBeacon Inc., whose largest shareholder is Pansend Life […]
Read MoreCARDIALEN IS DEVELOPING A LOW-ENERGY IMPLANTABLE DEFIBRILLATION THERAPY DESIGNED TO MORE GENTLY RESTORE THE HEART TO A NORMAL RHYTHM. Minneapolis, Oct. 10, 2018 – Cardialen, Inc., a medical device company […]
Read MoreLargest Series C venture round raised by a St. Louis bioscience company Galera Therapeutics, Inc., a clinical-stage drug discovery company, whose research and development is based in St. Louis, today […]
Read MoreBioGenerator portfolio company Benson Hill Biosystems, a crop improvement company unlocking the natural genetic diversity of plants, today announced the first close of its $60 million Series C financing. BioGenerator was […]
Read More